Bell Potter Healthcare Conference Presentation
Filed with ASX · · 24 pages · English
Clarity Pharmaceuticals Ltd. on 6ix
In the deck
Story so far
Earlier from Clarity Pharmaceuticals
- Recruitment target achieved for Phase II SAR-Bombesin trial
- Presentation for Wilsons Drug and Device Conference
- First patient treated with Cu-67 SAR-Bombesin
- Company Presentation E&P Small Cap Healthcare Conference
- BOP preliminary trial results presented at EANM 2023
Later from Clarity Pharmaceuticals
- SECuRE theranostic prostate cancer trial progresses
- undetectable PSA level with Cu-67 SAR-bisPSMA
- Phase III CLARIFY trial in prostate cancer commences
- Recruitment closes for a diagnostic Phase II trial in NETs
- First patient dosed in Phase III prostate cancer trial
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals